Colon Cancer Information Center
Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey? The Cancer Connect Colon Cancer Information Center has current, evidence-based information for you. Get the facts about colon cancer prevention, early detection, treatment, and survivorship, and stay up to date with ongoing colon cancer research that could impact your treatment decisions through our daily cancer news.
You are not alone—The CancerConnect Colon Cancer Community is the leading Social Media Application for Colon Cancer patients and caregivers seeking information, inspiration, and support in the wake of a cancer diagnosis. With over 50,000 members the network offers patients and caregivers a thriving community to support the many ongoing needs from diagnosis to survivorship. Login or register here.
On average Cyramza™ treated patients survived 13.3 months compared with 11.7 months for treatment with FOLFIRI alone. Aggressive Chemotherapy Doubles Survival of Patients with Metastatic Colon Cancer
Survival doubled when compared to a standard three drug regimen and Avastin. Erbitux Appears Superior to Avastin for Initial Colorectal Cancer Therapy
This is the first randomized clinical study directly comparing these two treatment regimens.
Cancer and its treatment can come with a variety of complications, some more serious... What is Genomics & How is it changing the Management of Cancer
You’ve probably heard of genetic testing for cancer susceptibility, but the more... Advanced Directives
Living Wills Every competent adult has, in most cases, the freedom to accept or refuse...
Colon Cancer Management
Meet an organization defined by out-of-the-box projects that inspire lifesaving... C3: Colorectal Cancer Coalition
Empowering Advocates and Pushing for a Cure by Diana Price Kate Murphy, director... Care Is Just a Call Away
The Colorectal CareLine: Providing Comprehensive Service to Patients in Times of...
Colon Cancer Clinical Trials
E5204 – Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-operative chemoradiation
CTSUE5202 – A randomized phase III clinical trial comparing 5-fluorouracil (5-FU), Leucovorin, Oxaliplatin (mFOLFOX6) and Bevacizumab in patients with stage II colon cancer at high risk for recurrence to determine prospectively the prognostic value of molecular markers.
07-141 – A Multi-center, Open-label, Randomized, Phase 2 Clinical Trial Evaluating Safety and Efficacy of FOLFIRI with Either Panitumumab or Bevacizumab as a Second-line Treatment in Subjects with Metastatic Colorectal Cancer